
RNA Therapy Market Intelligence Report - Global Forecast to 2027
Description
The Global RNA Therapy Market is projected to reach USD 4,686.50 million by 2027 from USD 1,567.35 million in 2021, at a CAGR 20.02% during the forecast period.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.
- The Americas RNA Therapy Market size was estimated at USD 613.02 million in 2021 and expected to reach USD 717.12 million in 2022, at a CAGR 19.80% to reach USD 1,812.91 million by 2027.
- The Asia-Pacific RNA Therapy Market size was estimated at USD 394.73 million in 2021 and expected to reach USD 468.08 million in 2022, at a CAGR 20.34% to reach USD 1,198.98 million by 2027.
- The Europe, Middle East & Africa RNA Therapy Market size was estimated at USD 559.60 million in 2021 and expected to reach USD 658.56 million in 2022, at a CAGR 20.04% to reach USD 1,674.60 million by 2027.
Market Segmentation & Coverage:
The report on rna therapy identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.
This research report categorizes the rna therapy to forecast the revenues and analyze the trends in each of the following sub-markets:
Technology:
- Enabled Technologies
- Inhibition
- Labeling
- Linear amplification
- Microarrays
- Purification
- qRT-PCR
- Enabling Technologies
- RNA Antisense Technologies
- MicroRNA
- Small interfering RNA
- RNA Interference Technologies
- RNA Antisense Technologies
Application:
- Cancer
- Cardiovascular
- Genetic Disorders
- Infectious Diseases
- Kidney Diseases
- Metabolic Disorders
- Oncology
- Retinal Diseases
End User:
- Academic Research
- Diagnostics
- Drug Discovery & Development
Region:
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- Arkansas
- California
- Florida
- Illinois
- Kentucky
- Minnesota
- New Jersey
- New Mexico
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Europe, Middle East & Africa
- France
- Germany
- Italy
- Netherlands
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- United Arab Emirates
- United Kingdom
Company Usability Profiles:
- Alnylam Pharmaceuticals, Inc.
- Arbutus Biopharma Corporation
- Arcturus Therapeutics Holdings Inc.
- Arrowhead Pharmaceuticals, Inc.
- Benitec Biopharma Limited
- Biogen Inc.
- BioNTech SE
- Cartesian Therapeutics, Inc.
- Cenix BioScience GmbH
- Dicerna Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- MiNA Therapeutics Limited
- Moderna, Inc.
- NeuBase Therapeutics, Inc.
- Nordic Nanovector ASA
- ProQR Therapeutics N.V.
- Sanofi S.A.
- Silence Therapeutics PLC
- Sirnaomics, Inc.
- Spark Therapeutics, Inc.
- Triplet Therapeutics, Inc.
Base Year: 2021
Estimated Year: 2022
Forecast Year: 2027
Base Year Value: USD 1,567.35 million
Estimated Year Value: USD 1,843.77 million
Forecast Year Value: USD 4,686.50 million
CAGR (%): 20.02%.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Market Overview
- 4. Americas RNA Therapy Market
- 4.1. Introduction
- 4.2. Argentina
- 4.3. Brazil
- 4.4. Canada
- 4.5. Mexico
- 4.6. United States
- 5. Asia-Pacific RNA Therapy Market
- 5.1. Introduction
- 5.2. Australia
- 5.3. China
- 5.4. India
- 5.5. Indonesia
- 5.6. Japan
- 5.7. Malaysia
- 5.8. Philippines
- 5.9. Singapore
- 5.10. South Korea
- 5.11. Taiwan
- 5.12. Thailand
- 6. Europe, Middle East & Africa RNA Therapy Market
- 6.1. Introduction
- 6.2. France
- 6.3. Germany
- 6.4. Italy
- 6.5. Netherlands
- 6.6. Qatar
- 6.7. Russia
- 6.8. Saudi Arabia
- 6.9. South Africa
- 6.10. Spain
- 6.11. United Arab Emirates
- 6.12. United Kingdom
- 7. Company Usability Profiles
- 7.1. Alnylam Pharmaceuticals, Inc.
- 7.2. Arbutus Biopharma Corporation
- 7.3. Arcturus Therapeutics Holdings Inc.
- 7.4. Arrowhead Pharmaceuticals, Inc.
- 7.5. Benitec Biopharma Limited
- 7.6. Biogen Inc.
- 7.7. BioNTech SE
- 7.8. Cartesian Therapeutics, Inc.
- 7.9. Cenix BioScience GmbH
- 7.10. Dicerna Pharmaceuticals, Inc.
- 7.11. Ionis Pharmaceuticals, Inc.
- 7.12. MiNA Therapeutics Limited
- 7.13. Moderna, Inc.
- 7.14. NeuBase Therapeutics, Inc.
- 7.15. Nordic Nanovector ASA
- 7.16. ProQR Therapeutics N.V.
- 7.17. Sanofi S.A.
- 7.18. Silence Therapeutics PLC
- 7.19. Sirnaomics, Inc.
- 7.20. Spark Therapeutics, Inc.
- 7.21. Triplet Therapeutics, Inc.
Pricing
Currency Rates